DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1889)

Irritable Bowel Syndrome | Current Treatment | Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis - IBS Without Diarrhea (Including IBS Constipation) - (US)

Irritable Bowel Syndrome | Current Treatment | Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis - IBS Without Diarrhea (Including IBS Constipation) - (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes, constipation predominant, diarrhea predominant, and mixed; however, prior to 2017, only two ICD-10 codes existed: IBS with diarrhea and IBS without diarrhea. For the purposes of this analysis, we focus on the IBS without diarrhea population, which includes IBS-constipation (IBS-C). Limited treatment options are available for IBS, and only a few drugs have secured an FDA approval for IBS-C. Current treatment options include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), guanylate cyclase-C agonists (Allergan’s Linzess and Synergy Pharmaceuticals’ Trulance), and bicyclic fatty acids (Takeda’s Amitiza), all of which are only moderately effective in treating the disease.

QUESTIONS ANSWERED

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed IBS without diarrhea (including IBS-C)patients? What are the quarterly trends in prescribing among recently treated and new diagnosed IBS without diarrhea (including IBS-C) patients?
  • How have Linzess and Trulance been integrated into the treatment algorithm?
  • What proportion of IBS without diarrhea (including IBS-C) patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of IBS without diarrhea (including IBS-C) patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with IBS without diarrhea (including IBS-C)?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing brand share.

Table of contents

  • Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis - IBS Without Diarrhea (Including IBS Constipation) - (US)
    • Treatment Algorithms Claims Data Analysis IBS Without Diarrhea (Including IBS Constipation) January 2019

Already a Client? Log in to access this report.

  • Pub Date: January 2019
  • Author(s): Mohit Nasa, MBA
  • Mohit Nasa is a Lead Insights analyst on the Immune and Inflammatory team at Decision Resources Group and has authored content for indications like asthma and rheumatoid arthritis. He holds a Bachelor’s degree in Pharmacy and has earned his MBA in marketing and CRM from Amity Business School. Prior to joining DRG, Mohit worked as a Senior Business analyst at Novartis where he was responsible for end to end market assessment, reporting analytics and related projects for Novartis’s asthma brand Xolair. Mohit has also worked as Brand Manager at Ozone pharma and an Account Manager for IMS Health.

Purchase Report

Recent reports:
You may also be interested in: